UA118656C2 - Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції - Google Patents

Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції

Info

Publication number
UA118656C2
UA118656C2 UAA201503523A UAA201503523A UA118656C2 UA 118656 C2 UA118656 C2 UA 118656C2 UA A201503523 A UAA201503523 A UA A201503523A UA A201503523 A UAA201503523 A UA A201503523A UA 118656 C2 UA118656 C2 UA 118656C2
Authority
UA
Ukraine
Prior art keywords
bremelanotide
treatment
sexual dysfunction
female sexual
application
Prior art date
Application number
UAA201503523A
Other languages
English (en)
Ukrainian (uk)
Inventor
Карл Спана
Роберт Джордан
Джеффрі Д. Еделсон
Original Assignee
Пелетін Текнолоджіз, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA118656(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пелетін Текнолоджіз, Інк. filed Critical Пелетін Текнолоджіз, Інк.
Publication of UA118656C2 publication Critical patent/UA118656C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
UAA201503523A 2012-11-05 2013-11-05 Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції UA118656C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US201361770535P 2013-02-28 2013-02-28
PCT/US2013/068386 WO2014071339A2 (en) 2012-11-05 2013-11-05 Uses of bremelanotide in therapy for female sexual dysfunction

Publications (1)

Publication Number Publication Date
UA118656C2 true UA118656C2 (uk) 2019-02-25

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201503523A UA118656C2 (uk) 2012-11-05 2013-11-05 Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції

Country Status (23)

Country Link
US (7) US9352013B2 (enExample)
EP (1) EP2916856B2 (enExample)
JP (1) JP6567971B2 (enExample)
KR (1) KR102253526B1 (enExample)
CN (2) CN117860866A (enExample)
AU (1) AU2013337341B2 (enExample)
BR (1) BR112015009936A8 (enExample)
DK (1) DK2916856T4 (enExample)
EA (1) EA032959B9 (enExample)
ES (1) ES2701444T5 (enExample)
FI (1) FI2916856T4 (enExample)
GE (2) GEP20196947B (enExample)
HK (1) HK1211227A1 (enExample)
IL (1) IL238276B (enExample)
MX (1) MX362610B (enExample)
MY (1) MY179755A (enExample)
NZ (1) NZ707246A (enExample)
PH (1) PH12015500915B1 (enExample)
PL (1) PL2916856T5 (enExample)
SG (1) SG11201502949QA (enExample)
UA (1) UA118656C2 (enExample)
WO (1) WO2014071339A2 (enExample)
ZA (1) ZA201503128B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) * 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
EP1289587B1 (en) * 2000-05-31 2005-08-03 Novo Nordisk A/S A disposable double pointed injection needle
EP1441750A4 (en) 2001-07-11 2006-10-18 Palatin Technologies Inc LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR
EP1819380B1 (en) * 2004-12-09 2018-04-04 West Pharmaceutical Services, Inc. Automatic injection and retraction syringe
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
AU2009257631B2 (en) * 2008-06-09 2014-07-24 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
AU2011242602B2 (en) * 2010-04-21 2015-06-18 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents

Also Published As

Publication number Publication date
KR102253526B1 (ko) 2021-05-18
JP6567971B2 (ja) 2019-08-28
AU2013337341A1 (en) 2015-05-07
BR112015009936A2 (pt) 2017-07-11
AU2013337341B2 (en) 2018-02-22
US9352013B2 (en) 2016-05-31
GEP20196947B (en) 2019-02-11
US20220362328A1 (en) 2022-11-17
US20140378392A1 (en) 2014-12-25
IL238276B (en) 2020-04-30
DK2916856T4 (da) 2024-01-22
PL2916856T3 (pl) 2019-02-28
MY179755A (en) 2020-11-12
WO2014071339A2 (en) 2014-05-08
US20210060120A1 (en) 2021-03-04
MX362610B (es) 2019-01-28
US10286034B2 (en) 2019-05-14
JP2016503406A (ja) 2016-02-04
DK2916856T3 (en) 2019-01-14
PH12015500915A1 (en) 2015-06-29
CN104755094A (zh) 2015-07-01
EA032959B1 (ru) 2019-08-30
US20240335502A1 (en) 2024-10-10
WO2014071339A3 (en) 2014-06-12
CN117860866A (zh) 2024-04-12
KR20150081345A (ko) 2015-07-13
US9700592B2 (en) 2017-07-11
EA201590760A1 (ru) 2015-10-30
EP2916856A4 (en) 2016-06-22
US20150231196A1 (en) 2015-08-20
US20180085425A1 (en) 2018-03-29
IL238276A0 (en) 2015-06-30
EA032959B9 (ru) 2019-11-27
PL2916856T5 (pl) 2024-01-29
EP2916856B1 (en) 2018-09-19
ZA201503128B (en) 2016-11-30
SG11201502949QA (en) 2015-06-29
US20190216888A1 (en) 2019-07-18
EP2916856A2 (en) 2015-09-16
BR112015009936A8 (pt) 2019-09-17
HK1211227A1 (en) 2016-05-20
FI2916856T4 (fi) 2024-01-15
GEAP201813826A (en) 2018-10-25
ES2701444T3 (es) 2019-02-22
PH12015500915B1 (en) 2015-06-29
MX2015005486A (es) 2015-11-13
CA2890081A1 (en) 2014-05-08
ES2701444T5 (es) 2024-05-21
NZ707246A (en) 2019-03-29
EP2916856B2 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
MX2021002321A (es) Nuevos metodos.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
NZ732507A (en) Improved compositions for treating muscular dystrophy
NZ714963A (en) Compositions and methods for treating anemia
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
PH12014500386A1 (en) Combination treatment for hepatitis c
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
UA117581C2 (uk) Протипухлинний лікарський засіб, який включає низькодозований гідрохлориду іринотекану гідрат
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12017500617A1 (en) Dosage regimen for pegylated interferon
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
UA118656C2 (uk) Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
ZA202102913B (en) Dosage regime